Aadi Bioscience, Inc. (NASDAQ:AADI) Q4 2022 Earnings Conference Call March 28, 2023 8:30 AM ET
Company Participants
Marcy Graham - Senior Vice President of Investor Relations and Corporate Communications
Neil Desai - Founder and Executive Chairman
Scott Giacobello - Interim Chief Executive Officer, President, and Chief Financial Officer
Loretta Itri - Chief Medical Officer
Conference Call Participants
Roger Song - Jefferies LLC
Ahu Demir - Ladenburg Thalmann & Company
Operator
Good day and thank you for standing by. Welcome to the Aadi Bioscience Fourth Quarter 2022 Earnings Call. At this time, all participants are in a listen-only mode. After the speakers' presentation, there will be a question-and-answer session. [Operator Instructions] Please be advised that today's conference is being recorded.
Now I will turn the call over to Marcy Graham, Senior Vice President of Investor Relations and Corporate Communications at Aadi Bioscience. Ms. Graham, please go ahead.
Marcy Graham
Thank you, Elizabeth. Good morning and welcome to the Aadi Bioscience conference call to review results of the fourth quarter and full year 2022 and to provide an update on our operations and good start in 2023. Joining me on the call today is Scott Giacobello, our CFO and Interim President and CEO who will provide an overview of financial and operational activity during the period, including an update on our continued commercial progress. Next will be our Chief Medical Officer, Dr. Loretta Itri, who will provide insights on our clinical developments and plans for 2023. We will open the line for questions at the end of the call following closing comments.
Before we get started, a quick reminder that statements made on the call today will include forward-looking statements. Actual events or results could differ materially from those expressed or implied by any forward-looking statements as a result of various risks, uncertainties and other factors, including those set forth in the Risk Factors section of our annual and quarterly reports filed with the Securities and Exchange Commission which can be found at www.sec.gov or on our website at www.aadibio.com.
In addition, any forward-looking statements made on this call represent our views only as of today, March 28, 2023 and should not be relied upon as representing our views as of any subsequent date. We specifically disclaim any obligation to update or revise any forward-looking statements.
With that, I will turn the call over to Scott for his opening statements. Scott?
Scott Giacobello